Matrix metalloproteinases and proangiogenic factors in testicular germ cell tumors

J BUON. 2010 Jan-Mar;15(1):116-21.

Abstract

Purpose: Testicular cancer is the most frequent solid tumor in young male adults and a disease with elusive pathogenesis. The purpose of this study was to determine the role of matrix metalloproteinases and angiogenic factors in the pathogenesis of testicular germ cell tumors (GCTs).

Methods: Between 2003 and 2006 we measured the serum levels of matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9), tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), vascular endothelial growth factor A (VEGF-A), basic fibroblast growth factor (bFGF), platelet derived growth factor BB (PDGF-BB) and angiopoietin 2 (Ang-2) in 50 patients with testicular GCTs, at baseline, one month after the completion of the second cycle of chemotherapy and one year after the completion of chemotherapy, and in 16 male age-matched controls at baseline.

Results: At baseline, mean TIMP-2 value was lower in patients than controls, mean MMP-2/TIMP-2 ratio was higher in patients than controls and MMP9/TIMP-2 ratio was also higher. Ang-2 value was higher in patients than controls and bFGF value was also higher. Comparisons of the same parameters were also made among the 3 consecutive serum samples of the patients. All parameters normalized after chemotherapy except Ang-2 which remained elevated.

Conclusion: The present study supports the hypothesis that tumor invasion and angiogenesis play a role in testicular GCTs pathogenesis. Also an interesting hypothesis was formed, concerning the role of elevated levels of Ang-2 found in testicular GCTs patients in the pathogenesis of the increased long term cardiovascular morbidity of these patients. Larger prospective studies are needed to confirm our results.

MeSH terms

  • Adult
  • Angiogenic Proteins / blood*
  • Angiopoietin-2 / blood
  • Antineoplastic Agents / therapeutic use
  • Becaplermin
  • Case-Control Studies
  • Chemotherapy, Adjuvant
  • Fibroblast Growth Factor 2 / blood
  • Humans
  • Male
  • Matrix Metalloproteinase 2 / blood
  • Matrix Metalloproteinase 9 / blood
  • Matrix Metalloproteinases / blood*
  • Neoplasm Invasiveness
  • Neoplasms, Germ Cell and Embryonal / blood*
  • Neoplasms, Germ Cell and Embryonal / enzymology
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / therapy
  • Orchiectomy
  • Platelet-Derived Growth Factor / metabolism
  • Proto-Oncogene Proteins c-sis
  • Testicular Neoplasms / blood*
  • Testicular Neoplasms / enzymology
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / therapy
  • Time Factors
  • Tissue Inhibitor of Metalloproteinase-2 / blood
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Angiogenic Proteins
  • Angiopoietin-2
  • Antineoplastic Agents
  • Platelet-Derived Growth Factor
  • Proto-Oncogene Proteins c-sis
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • Tissue Inhibitor of Metalloproteinase-2
  • Becaplermin
  • Matrix Metalloproteinases
  • MMP2 protein, human
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9